Jefferies Financial Group Inc. Acquires New Holdings in Pediatrix Medical Group, Inc. $MD

Jefferies Financial Group Inc. bought a new position in Pediatrix Medical Group, Inc. (NYSE:MD) in the 3rd quarter, HoldingsChannel reports. The fund bought 63,410 shares of the company’s stock, valued at approximately $1,062,000.

Several other large investors also recently made changes to their positions in MD. Victory Capital Management Inc. boosted its position in shares of Pediatrix Medical Group by 30.7% during the third quarter. Victory Capital Management Inc. now owns 4,126,207 shares of the company’s stock worth $69,114,000 after buying an additional 968,553 shares during the period. Dimensional Fund Advisors LP raised its stake in Pediatrix Medical Group by 2.5% during the 3rd quarter. Dimensional Fund Advisors LP now owns 3,399,778 shares of the company’s stock valued at $56,942,000 after acquiring an additional 81,554 shares in the last quarter. American Century Companies Inc. boosted its position in Pediatrix Medical Group by 38.9% during the 3rd quarter. American Century Companies Inc. now owns 2,682,976 shares of the company’s stock worth $44,940,000 after acquiring an additional 751,109 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Pediatrix Medical Group by 20.5% in the third quarter. JPMorgan Chase & Co. now owns 827,075 shares of the company’s stock worth $13,854,000 after purchasing an additional 140,577 shares in the last quarter. Finally, Dana Investment Advisors Inc. grew its stake in shares of Pediatrix Medical Group by 5.6% in the third quarter. Dana Investment Advisors Inc. now owns 801,462 shares of the company’s stock worth $13,424,000 after purchasing an additional 42,162 shares in the last quarter. Institutional investors and hedge funds own 97.71% of the company’s stock.

Insider Buying and Selling

In related news, CEO Mark S. Ordan sold 23,000 shares of the stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $22.41, for a total transaction of $515,430.00. Following the completion of the sale, the chief executive officer directly owned 302,805 shares of the company’s stock, valued at $6,785,860.05. This represents a 7.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.90% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Zacks Research cut shares of Pediatrix Medical Group from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 23rd. Weiss Ratings restated a “hold (c+)” rating on shares of Pediatrix Medical Group in a research report on Monday, December 29th. UBS Group reduced their price target on shares of Pediatrix Medical Group from $23.00 to $22.00 and set a “neutral” rating for the company in a research note on Tuesday, February 24th. Truist Financial decreased their price objective on shares of Pediatrix Medical Group from $24.00 to $21.00 and set a “hold” rating for the company in a report on Thursday, February 19th. Finally, Deutsche Bank Aktiengesellschaft set a $19.00 target price on Pediatrix Medical Group in a report on Friday, February 20th. One investment analyst has rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $19.80.

Pediatrix Medical Group Price Performance

Shares of Pediatrix Medical Group stock opened at $19.42 on Friday. Pediatrix Medical Group, Inc. has a 52 week low of $11.84 and a 52 week high of $24.99. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.66. The stock has a market cap of $1.61 billion, a PE ratio of 10.01 and a beta of 0.79. The company’s 50-day moving average price is $20.97 and its two-hundred day moving average price is $19.99.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings data on Thursday, February 19th. The company reported $0.50 earnings per share for the quarter, missing the consensus estimate of $0.53 by ($0.03). The business had revenue of $493.77 million for the quarter, compared to the consensus estimate of $486.23 million. Pediatrix Medical Group had a net margin of 8.64% and a return on equity of 19.59%. The business’s revenue for the quarter was down 1.7% on a year-over-year basis. During the same quarter last year, the business posted $0.51 EPS. As a group, sell-side analysts anticipate that Pediatrix Medical Group, Inc. will post 1.38 EPS for the current fiscal year.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.